» Articles » PMID: 39739690

Deciphering the Interactome of Ataxin-2 and TDP-43 in IPSC-derived Neurons for Potential ALS Targets

Overview
Journal PLoS One
Date 2024 Dec 31
PMID 39739690
Authors
Affiliations
Soon will be listed here.
Abstract

Ataxin-2 is a protein containing a polyQ extension and intermediate length of polyQ extensions increases the risk of Amyotrophic Lateral Sclerosis (ALS). Down-regulation of Ataxin-2 has been shown to mitigate TDP-43 proteinopathy in ALS models. To identify alternative therapeutic targets that can mitigate TDP-43 toxicity, we examined the interaction between Ataxin-2 and TDP-43. Co-immunoprecipitation demonstrated that Ataxin-2 and TDP-43 interact, that their interaction is mediated through the RNA recognition motif (RRM) of TDP-43, and knocking down Ataxin-2 or mutating the RRM domains rescued TDP-43 toxicity in an iPSC-derived neuronal model with TDP-43 overexpression. To decipher the Ataxin-2 and TDP-43 interactome, we used co-immunoprecipitation followed by mass spectrometry to identify proteins that interacted with Ataxin-2 and TDP-43 under conditions of endogenous or overexpressed TDP-43 in iPSC-derived neurons. Multiple interactome proteins were differentially regulated by TDP-43 overexpression and toxicity, including those involved in RNA regulation, cell survival, cytoskeleton reorganization, protein modification, and diseases. Interestingly, the RNA-binding protein (RBP), TAF15 which has been implicated in ALS was identified as a strong binder of Ataxin-2 in the condition of TDP-43 overexpression. Together, this study provides a comprehensive annotation of the Ataxin-2 and TDP-43 interactome and identifies potential therapeutic pathways and targets that could be modulated to alleviate Ataxin-2 and TDP-43 interaction-induced toxicity in ALS.

References
1.
Scoles D, Meera P, Schneider M, Paul S, Dansithong W, Figueroa K . Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017; 544(7650):362-366. PMC: 6625650. DOI: 10.1038/nature22044. View

2.
Starr A, Sattler R . Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Brain Res. 2018; 1693(Pt A):98-108. PMC: 5997509. DOI: 10.1016/j.brainres.2018.02.011. View

3.
Ou S, Wu F, Harrich D, Gaynor R . Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995; 69(6):3584-96. PMC: 189073. DOI: 10.1128/JVI.69.6.3584-3596.1995. View

4.
Kim G, Nakayama L, Blum J, Akiyama T, Boeynaems S, Chakraborty M . Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. Cell Rep. 2022; 41(4):111508. PMC: 9664452. DOI: 10.1016/j.celrep.2022.111508. View

5.
Brown A, Wilkins O, Keuss M, Hill S, Zanovello M, Lee W . TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022; 603(7899):131-137. PMC: 8891020. DOI: 10.1038/s41586-022-04436-3. View